Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
PRR11 promotes ccRCC tumorigenesis by regulating E2F1 stability
Siming Chen, Zhiwen He, Tianchen Peng, Fenfang Zhou, Gang Wang, Kaiyu Qian, Lingao Ju, Yu Xiao, Xinghuan Wang
Siming Chen, Zhiwen He, Tianchen Peng, Fenfang Zhou, Gang Wang, Kaiyu Qian, Lingao Ju, Yu Xiao, Xinghuan Wang
View: Text | PDF
Research Article Cell biology Nephrology

PRR11 promotes ccRCC tumorigenesis by regulating E2F1 stability

  • Text
  • PDF
Abstract

Proline rich 11 (PRR11), a novel tumor-related gene, has been identified in different tumors. However, the relevant biological functions of PRR11 in human clear cell renal cell carcinoma (ccRCC) have not been studied. In this study, we first identified PRR11 as a biomarker of ccRCC and predictor of poor prognosis by bioinformatics. Then, we showed that PRR11 silencing substantially reduced ccRCC cell proliferation and migration in vitro and in vivo. Importantly, we found that PRR11 induced the degradation of the E2F1 protein through its interaction with E2F1, and PRR11 reduced the stability of the E2F1 protein in ccRCC cells, thereby affecting cell cycle progression. Further results indicated that the downregulation of E2F1 expression partially reversed the changes in ccRCC cell biology caused by PRR11 deletion. In addition, we showed that PRR11 was a target gene of c-Myc. The transcription factor c-Myc may have promoted the expression of PRR11 in ccRCC cells by binding to the PRR11 promoter region, thereby accelerating the progression of ccRCC. In summary, we found that PRR11 served as an oncogene in ccRCC, and PRR11 reduced the protein stability of E2F1 and could be activated by c-Myc.

Authors

Siming Chen, Zhiwen He, Tianchen Peng, Fenfang Zhou, Gang Wang, Kaiyu Qian, Lingao Ju, Yu Xiao, Xinghuan Wang

×

Figure 6

c-Myc promoted the expression of PRR11 in ccRCC cells by binding to the PRR11 promoter.

Options: View larger image (or click on image) Download as PowerPoint
c-Myc promoted the expression of PRR11 in ccRCC cells by binding to the ...
(A and B) The mRNA expression levels of PRR11 and c-Myc in ccRCC tissues were analyzed (n = 11). (C and D) The effects of changes in c-Myc expression on PRR11 expression were analyzed at the mRNA and protein levels (n = 3). (E) The binding site of c-Myc was obtained from the JASPAR database. (F) Schematic of the PRR11 promoter region. The box (P1-P4) indicates the sequence region covered by the ChIP-qPCR primers. The red area represents the core binding element. (G) ChIP-qPCR assay of the enrichment of c-Myc in the PRR11 promoter region (n = 3). (H) Luciferase activity verified that c-Myc promoted the transcription of PRR11 in 293T cells (n = 4). The upregulation of c-Myc expression was detected by Western blotting (n = 3). (I) A luciferase assay was performed on the WT and mutant promoters of PRR11 in ACHN cells (n = 4). The data are shown as mean ± SD. Two-tailed t test (A–C, left; and G), 1-way ANOVA with Dunnett’s multiple comparisons test (C, right; and H), and 2-way ANOVA with Tukey’s multiple comparisons test (I) analyses were performed. NS, *P < 0.05, **P < 0.01, ***P < 0.001. PRR11, proline rich 11; ccRCC, clear cell renal cell carcinoma.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts